SCHEMBL288392

SCHEMBL288392

CSc1ccc2c(c1)CCN2c1ncnc(Cl)c1C#N

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EIF4E P06730 2/20 0.39
MKNK1 Q9BUB5 2/20 0.39
MKNK2 Q9HBH9 2/20 0.39
EGFR P00533 4/20 0.37
CSF1R P07333 1/20 0.36
HPGD P15428 4/20 0.36
KDM4E B2RXH2 3/20 0.36
HSD17B10 Q99714 3/20 0.36
HTT P42858 3/20 0.36
HTR2A P28223 2/20 0.36
HTR2C P28335 2/20 0.36
ALDH1A1 P00352 2/20 0.36
MEN1 O00255 1/20 0.36
MAPK1 P28482 1/20 0.36
KMT2A Q03164 1/20 0.36
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36
HTR2B P41595 1/20 0.34
PDGFRB P09619 2/20 0.33
KDR P35968 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL288160 0.75 ROCK1 (0.41) EIF4EMKNK1MKNK2HTR2AHTR2C
SCHEMBL16071466 0.67 SMN1; SMN2 (0.58) MKNK1MKNK2EGFRCSF1RHPGD
SCHEMBL21524783 0.67 TUBB4A (0.45) EIF4EMKNK1MKNK2EGFRCSF1R
SCHEMBL4496461 0.65 GPR119 (0.42) EIF4EMKNK1MKNK2GPR119
SCHEMBL4496039 0.64 HTT (0.35) HTTHTR2AHTR2CMEN1KMT2A
SCHEMBL1673854 0.63 PIP4K2A (0.47) EGFRHTTTSHRMAPTRXFP1
SCHEMBL288822 0.62 SRD5A1 (0.53) HPGDKDM4EALDH1A1MEN1KMT2A
SCHEMBL1366102 0.62 SMN1; SMN2 (0.55) MKNK1MKNK2EGFRCSF1RHPGD
SCHEMBL8645023 0.61 EGFR (0.73) EGFRCSF1RPDGFRBKDRTUBB4A
SCHEMBL23761414 0.61 SRD5A1 (0.45) EIF4EMKNK1MKNK2EGFRCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427450-A1 GPR 119 MODULATORS Pfizer Inc. (US) 2012-03-14 EP disclosed
EP-2427448-A1 Gpr 119 modulators Pfizer Inc. (US) 2012-03-14 EP disclosed
US-20120052130-A1 GPR 119 MODULATORS PFIZER INC. 2012-03-01 US disclosed
US-20120052130-A1 GPR 119 MODULATORS PFIZER INC. 2012-03-01 US disclosed
US-20120052130-A1 GPR 119 MODULATORS PFIZER INC. 2012-03-01 US disclosed
WO-2010128414-A1 GPR 119 MODULATORS PFIZER INC. (US) 2010-11-11 WO disclosed
WO-2010128414-A1 GPR 119 MODULATORS PFIZER INC. (US) 2010-11-11 WO disclosed
WO-2010128425-A1 GPR 119 MODULATORS PFIZER INC. (US) 2010-11-11 WO disclosed
WO-2010128425-A1 GPR 119 MODULATORS PFIZER INC. (US) 2010-11-11 WO disclosed
US-20100285145-A1 GPR 119 MODULATORS PFIZER INC 2010-11-11 US disclosed
US-20100285145-A1 GPR 119 MODULATORS PFIZER INC 2010-11-11 US disclosed
US-20100285145-A1 GPR 119 MODULATORS PFIZER INC 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120052130-A1 GPR 119 MODULATORS GPR119, GPR39, GPR65 EIF4E 3058/4885MKNK1 3327/4885MKNK2 2809/4885
US-20100285145-A1 GPR 119 MODULATORS GPR119, GPR65, GPR39 EIF4E 3569/4885MKNK1 2927/4885MKNK2 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.